Drug intelligence / Profile preview

donzakimig

Development stage: Phase 2
Lead developer: UCB
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Donzakimig is a bispecific monoclonal antibody developed by UCB Biopharma that targets both interleukin-13 (IL-13) and interleukin-22 (IL-22). It is being investigated primarily for the treatment of atopic dermatitis. The drug acts as an immunomodulator by inhibiting the activity of IL-13 and IL-22, cytokines involved in inflammatory pathways associated with skin disorders. Donzakimig is currently in phase 1/2 clinical trials for atopic dermatitis[2][4][8].

Other names: donzakimigUCB1381UCB-1381UCB 1381

Targets

IL-13 (Interleukin-13)IL22 (Interleukin 22)

Beyond the preview

Go deeper on donzakimig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donzakimig.

Explore the full profile